

Paul R Walker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1916346/publications.pdf>

Version: 2024-02-01

33
papers

1,540
citations

394421

19
h-index

454955

30
g-index

59
all docs

59
docs citations

59
times ranked

2277
citing authors

#	ARTICLE	IF	CITATIONS
1	Homing Phenotypes of Tumor-Specific CD8 T Cells Are Predetermined at the Tumor Site by Crosspresenting APCs. <i>Immunity</i> , 2005, 22, 175-184.	14.3	209
2	Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. <i>Brain</i> , 2012, 135, 1042-1054.	7.6	192
3	Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. <i>Oncolmunology</i> , 2018, 7, e1501137.	4.6	120
4	Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review. , 2020, 8, e001408.		100
5	Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. <i>Neuro-Oncology</i> , 2019, 21, 923-933.	1.2	89
6	T-cell immune responses in the brain and their relevance for cerebral malignancies. <i>Brain Research Reviews</i> , 2003, 42, 97-122.	9.0	77
7	Peptides as cancer vaccines. <i>Current Opinion in Pharmacology</i> , 2019, 47, 20-26.	3.5	75
8	Cutting Edge: Cross-Presentation as a Mechanism for Efficient Recruitment of Tumor-Specific CTL to the Brain. <i>Journal of Immunology</i> , 2003, 171, 2187-2191.	0.8	58
9	Harnessing Microglia and Macrophages for the Treatment of Glioblastoma. <i>Frontiers in Pharmacology</i> , 2019, 10, 506.	3.5	55
10	Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer. <i>Journal of Controlled Release</i> , 2020, 328, 932-941.	9.9	55
11	All in the head: obstacles for immune rejection of brain tumours. <i>Immunology</i> , 2002, 107, 28-38.	4.4	53
12	An update on actively targeted liposomes in advanced drug delivery to glioma. <i>International Journal of Pharmaceutics</i> , 2021, 602, 120645.	5.2	51
13	Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity. <i>Cancer Research</i> , 2015, 75, 3020-3031.	0.9	50
14	Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. <i>Oncolmunology</i> , 2018, 7, e1391972.	4.6	42
15	Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. , 2021, 9, e002181.		42
16	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. <i>Frontiers in Oncology</i> , 2016, 6, 256.	2.8	39
17	Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 2887-2896.	5.4	33
18	Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants. <i>Molecular Therapy</i> , 2016, 24, 1675-1685.	8.2	29

#	ARTICLE	IF	CITATIONS
19	Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine. JCI Insight, 2019, 4, .	5.0	28
20	ER ⁺ mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells. EMBO Journal, 2017, 36, 1493-1512.	7.8	27
21	Identification of a novel population of highly cytotoxic cMet-expressing CD8 ⁺ T lymphocytes. EMBO Reports, 2017, 18, 1545-1558.	4.5	22
22	Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing. PLoS ONE, 2016, 11, e0162105.	2.5	17
23	Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells. Communications Biology, 2021, 4, 718.	4.4	14
24	The CD40/CD40L axis in glioma progression and therapy. Neuro-Oncology, 2015, 17, 1428-1430.	1.2	12
25	Glioma-Derived Extracellular Vesicles – Far More Than Local Mediators. Frontiers in Immunology, 2021, 12, 679954.	4.8	11
26	Glioma Stemlike Cells Enhance the Killing of Glioma Differentiated Cells by Cytotoxic Lymphocytes. PLoS ONE, 2016, 11, e0153433.	2.5	8
27	An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin. Biology, 2020, 9, 264.	2.8	7
28	Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin). JCI Insight, 2021, 6, .	5.0	7
29	Immunotherapy for Glioma: From Illusion to Realistic Prospects?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 51-59.	3.8	5
30	Cell-penetrating peptides—the Swiss Army knife of cancer vaccines. OncoImmunology, 2016, 5, e1095435.	4.6	5
31	Getting by with a little help from the right CD4 ⁺ T cells. OncoImmunology, 2013, 2, e25772.	4.6	4
32	Untangling macrophage/microglia complexity in glioblastoma subtypes to elucidate the impact of CSF1R inhibition. Neuro-Oncology, 2022, 24, 598-600.	1.2	4
33	P01.122 Safety, immunogenicity and optimization of the IMA950 multipeptide vaccine combined with Poly-ICLC in newly diagnosed HLA-A2 malignant glioma patients. Neuro-Oncology, 2018, 20, iii260-iii260.	1.2	0